Grail Stock Rises on Investor Optimism Despite Mixed ASCO Presentation
Shares of Grail (NASDAQ: GRAL) rose by 11.5% following mixed investor reactions to its recent presentation at the American Society of Clinical Oncology conference, where data from trials did not strongly support FDA approval or insurance coverage for its Galleri test.
Topics: ASCO conference FDA approval Grail MCED test